Building a pharmaceutical product from a compound or active ingredient into a stable, manufacturable, and regulatory-ready dosage form is one of the most technically demanding stages in drug development. For startup founders, biotech executives, and emerging pharmaceutical companies, the decision of which external partner to work with at this stage carries significant consequences — not just for timelines, but for the long-term viability of the product itself.
Unlike many other vendor relationships in life sciences, formulation partnerships directly shape what reaches the clinic, how regulators view your submission, and whether your compound survives scale-up. Yet many founders approach this selection process without a clear framework, often defaulting to name recognition, location, or price — none of which are reliable proxies for capability or fit.
This guide is intended for those actively evaluating formulation partners in the US. It addresses the substantive questions that matter at each stage of the decision, and explains why those questions connect to outcomes rather than simply checkboxes.
Understanding What a Formulation Company Actually Does — and What to Look For
A drug product formulation company does far more than combine ingredients and produce a batch. It translates scientific and clinical intent into a physical product that must behave consistently across stability conditions, scale, patient populations, and manufacturing environments. This work involves preformulation studies, excipient selection, compatibility analysis, prototype development, analytical method development, and the creation of technical documentation that supports regulatory filings.
When evaluating a drug product formulation company, the first distinction to make is between companies that offer formulation as part of a broader contract manufacturing service and those that are formulation-focused as a primary discipline. Both can be suitable depending on your stage, but the depth of scientific thinking, the quality of feasibility assessment, and the rigor of early development work tend to differ meaningfully between them.
Why Formulation Expertise Must Precede Manufacturing Capability
Many founders prioritize scale-up and manufacturing capacity when selecting a formulation partner, which reverses the actual sequence of risk. The greatest point of failure in drug product development is not production volume — it is the formulation itself. A poorly characterized or underdeveloped formulation will create problems at every downstream stage: inconsistent bioavailability, failed stability studies, manufacturing batch failures, and ultimately regulatory deficiencies.
The right formulation partner invests significant effort in the design phase before a single prototype batch is made. This includes understanding your molecule’s physical and chemical properties, identifying potential stability liabilities, selecting excipients that support both performance and regulatory acceptability, and anticipating how the formulation will behave under different storage and handling conditions. Companies that rush toward prototype production without adequate preformulation work are a signal worth noting early in the evaluation process.
Regulatory Alignment and Quality Systems
In the US pharmaceutical context, regulatory expectations are embedded into the formulation process itself, not applied afterward. The FDA’s quality-by-design framework, as outlined in guidance documents aligned with ICH Q8 and Q9 guidelines, expects that formulation decisions be scientifically justified and that critical quality attributes be understood throughout development. A formulation partner operating in this environment must not only be familiar with these frameworks — they must actively apply them in their documentation and decision-making.
What Quality Systems Reveal About a Partner’s Maturity
A company’s quality system is the infrastructure through which all formulation work is controlled, recorded, and assured. For founders preparing for IND submissions, NDA filings, or technology transfers, this infrastructure determines whether the work produced can actually be used in a regulatory context.
Key indicators of quality system maturity include how the company manages deviations and out-of-specification results, how it handles change control during development, and whether its analytical laboratories operate under appropriate compliance standards. A formulation partner working in GMP or GMP-ready conditions is not simply a regulatory preference — it protects the usability of your data and reduces the risk of having to repeat costly studies because documentation was insufficient or processes were not controlled.
The Importance of Documentation That Transfers
Development reports, batch records, analytical methods, and stability protocols produced by your formulation partner will eventually need to transfer — either to a manufacturing site, to a regulatory submission, or to an acquiring company’s technical team. Documentation that is internally coherent but lacks the structure, completeness, or scientific rationale expected by external reviewers creates significant rework burdens later. Assessing the quality of a potential partner’s documentation practices before engagement is a reasonable and important step.
Scientific Communication and Transparency During Development
Drug product development rarely proceeds in a straight line. Formulations fail stability testing, excipients create unexpected interactions, manufacturing processes require adjustment, and clinical feedback sometimes drives reformulation. How a formulation partner communicates during these moments — not during the sales process — is one of the most important indicators of a productive long-term relationship.
The Risk of Partners Who Minimize Problems
Founders who have worked with multiple contract formulation organizations often point to communication failures as the most operationally damaging aspect of a poor partnership. This includes receiving delayed notification of batch failures, getting vague or overly optimistic assessments of stability outcomes, or discovering that a technical issue was known internally weeks before it was shared with the client.
These patterns are difficult to detect in a sales conversation, but they become visible through references, through the quality of communication in a feasibility discussion, and through how the technical team responds to probing questions. Partners who can clearly articulate what they do not know, what risks remain open, and what decisions require your input as a sponsor tend to be more reliable in practice than those who project uniform confidence.
Asking the Right Questions in Technical Discussions
Before engagement, request a technical discussion with the scientists who would actually work on your project, not only business development representatives. Use this conversation to assess whether the team asks substantive questions about your molecule, your clinical goals, and your target patient population. A formulation team thinking carefully about your product will want to understand the intended route of administration, the patient compliance context, and the regulatory pathway — not just the compound’s solubility class.
Therapeutic and Dosage Form Experience
Formulation science is not a single discipline. Developing a modified-release oral solid dosage form requires different expertise, equipment, and analytical capabilities than developing a parenteral product, a transdermal system, or a pediatric liquid formulation. A drug product formulation company with a strong track record in one category may have limited practical experience in another.
How to Evaluate Relevant Experience Without Being Misled by Portfolio Breadth
Many formulation organizations list a wide range of dosage form capabilities on their websites. Evaluating whether that breadth reflects genuine depth requires a different approach. Ask specifically how many projects of your dosage form type the company has completed in the last few years, how many reached clinical or commercial stage, and whether the team has dealt with challenges specific to your molecule class — poor solubility, chemical instability, narrow therapeutic index, or pediatric dosing requirements, for example.
References from sponsors who worked on similar programs are more informative than general client testimonials. If a company cannot offer relevant references or declines to share them, that is worth factoring into your assessment.
Scale-Up Planning and Technology Transfer Readiness
The formulation developed at bench or pilot scale must eventually transfer to a manufacturing environment capable of producing clinical or commercial quantities. This transition is a source of significant risk if the formulation was developed without considering manufacturing process constraints, equipment variability, and the analytical challenges that emerge at larger batch sizes.
Why Formulation Decisions Made Early Affect Manufacturing Later
Process understanding — the relationship between formulation variables, process parameters, and product quality — must be built into development, not reconstructed after the fact. A formulation partner that thinks about manufacturability from the beginning of the program will make excipient and process choices that translate more reliably at scale. One that optimizes only for laboratory-scale performance may produce a formulation that is difficult or impossible to reproduce consistently in a commercial setting.
Evaluating a partner’s approach to scale-up readiness includes understanding whether they have internal manufacturing suites or manufacturing partnerships, how they design their process characterization studies, and what their history looks like with technology transfers to third-party sites. A company that has successfully transferred formulations to multiple contract manufacturers demonstrates a level of process discipline that matters for your program’s downstream phases.
Practical Checklist for the Evaluation Process
Before finalizing any formulation partnership, the following considerations should be addressed with clear answers — not assumptions:
- Confirm that the company has direct, verifiable experience with your specific dosage form and route of administration, not just adjacent categories.
- Review the quality of their development reports and analytical documentation, ideally using a redacted example relevant to your program type.
- Assess whether their quality systems support GMP or GMP-ready conditions appropriate to your regulatory stage.
- Evaluate the scientific team’s ability to articulate risks and open questions honestly, particularly in early feasibility discussions.
- Understand how they handle project communication during periods of unexpected results or technical challenges.
- Clarify their approach to scale-up and technology transfer, including their process characterization methodology and manufacturing relationships.
- Obtain references from sponsors with programs at a similar stage and dosage form to your own.
Conclusion
Selecting a drug product formulation company is a decision with long-range consequences that extend well beyond the early development phase. The partner you choose will shape the scientific foundation of your regulatory submissions, the reliability of your clinical supply, and the ease with which your program moves toward commercialization. Rushing this decision — or prioritizing criteria that are easy to evaluate over those that actually matter — is one of the most common and costly mistakes in early drug development.
The evaluation process described in this article is not exhaustive, but it is grounded in the factors that most consistently differentiate capable, reliable partners from those who create downstream problems. Taking the time to assess regulatory alignment, scientific transparency, relevant experience, and manufacturing readiness before signing any agreement is an investment that pays consistent returns throughout the development lifecycle.
For founders building in the US pharmaceutical space, the market includes formulation partners of widely varying quality and specialization. A structured, deliberate approach to selection — one that goes beyond geography and price — is the most reliable way to protect both your compound and your program’s timeline from avoidable risk.
